Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the acute leukemia working party of the European society for blood and marrow transplantation

CJ Lee, BN Savani, M Mohty, M Labopin, Annalisa Ruggeri, C Schmid, F Baron, J Esteve, NC Gorin, S Giebel, F Ciceri, A Nagler

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic blood or marrow hematopoietic cell transplantation continues to be the most potent anti-leukemic treatment for adult patients with standard, high-risk, or chemo-refractory acute myeloid leukemia. Until recently, this procedure was generally limited to those recipients who had an available matched-sibling donor or matched-unrelated donor. Technical advances in graft cell processing and manipulation, control of bidirectional T cell alloreactivity, graft-versus- host disease prophylaxis, and other supportive measures in haploidentical transplantation now enable nearly all patients with acute myeloid leukemia to benefit from the graft-versus-leukemia effect with substantial reduction in procedure-related mortality. Over recent years, haploidentical donors have been increasingly adopted as a valid donor source in allogeneic hematopoietic cell transplantation for acute myeloid leukemia in the absence of an HLA-matched donor. Among centers of the European Society for Blood and Marrow Transplantation, the use of haploidentical related donor transplantation has increased by 250% since 2010, and 291% since 2005. On behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize recent utilization trends in haploidentical transplantation for acute myeloid leukemia and describe the transformative changes in haploidentical hematopoietic cell transplantation techniques over the past decade, which have led to the current widespread use of this procedure. Furthermore, we review the efficacy of haploidentical hematopoietic cell transplantation for acute myeloid leukemia from available studies, including preliminary comparative studies, and bring attention to remaining unanswered questions and directions for future research. We conclude this report with our recommendations for the role of haploidentical hematopoietic cell transplantation in acute myeloid leukemia. © 2017 Ferrata Storti Foundation.
Original languageEnglish
Pages (from-to)1810-1822
Number of pages13
JournalHaematologica
Volume102
Issue number11
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the acute leukemia working party of the European society for blood and marrow transplantation'. Together they form a unique fingerprint.

Cite this